Zhang W - Search Results

1

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).

Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Tang X, Yu J, Maher E, Feng H, Yao S, Keegan P, Wang J. Wang Z, et al. Among authors: zhang w, zhang z, zhang x. J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7. J Clin Oncol. 2023. PMID: 36206498 Free PMC article. Clinical Trial.

2

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer.

Yang Z, Chen Y, Wang Y, Hu M, Qian F, Zhang Y, Zhang B, Zhang W, Han B. Yang Z, et al. Among authors: zhang b, zhang w, zhang y. Front Immunol. 2022 Feb 14;13:807575. doi: 10.3389/fimmu.2022.807575. eCollection 2022. Front Immunol. 2022. PMID: 35237263 Free PMC article.

3

Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.

Chen Y, Wang Y, Yang Z, Hu M, Lu J, Zhang Y, Qian F, Zhang B, Wang S, Wang K, Zhang W, Han B. Chen Y, et al. Among authors: zhang b, zhang w, zhang y. Thorac Cancer. 2022 Mar;13(5):732-741. doi: 10.1111/1759-7714.14312. Epub 2022 Jan 21. Thorac Cancer. 2022. PMID: 35060346 Free PMC article.

4

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).

Zhang B, Shi C, Gao Z, Zhong H, Xiong L, Gu A, Wang W, Chu T, Zhang W, Wang H, Zhang X, Zhong R, Han B. Zhang B, et al. Among authors: zhang w, zhang x. BMC Cancer. 2022 Mar 19;22(1):294. doi: 10.1186/s12885-022-09409-3. BMC Cancer. 2022. PMID: 35305596 Free PMC article.

5

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.

Lu J, Chu T, Liu H, Hu M, Lou Y, Zhang Y, Gao Z, Zhang W, Zhang X, Wang H, Zhong H, Han B. Lu J, et al. Among authors: zhang w, zhang x, zhang y. Chin J Cancer Res. 2022 Feb 28;34(1):28-39. doi: 10.21147/j.issn.1000-9604.2022.01.03. Chin J Cancer Res. 2022. PMID: 35355930 Free PMC article.

6

Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.

Wang Y, Chen Y, Yang Z, Qian F, Hu M, Lu J, Zhang Y, Zhang W, Wang K, Han B. Wang Y, et al. Among authors: zhang w, zhang y. Ann Surg Oncol. 2022 Sep;29(9):5666-5678. doi: 10.1245/s10434-022-11610-4. Epub 2022 May 11. Ann Surg Oncol. 2022. PMID: 35543906 Review.

7

Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients.

Lu J, Wu J, Lou Y, Shi Q, Xu J, Zhang L, Nie W, Qian J, Wang Y, Zhang Y, Jiao J, Zhang X, Zhang W, Wang H, Chu T, Zhong H, Han B. Lu J, et al. Among authors: zhang l, zhang w, zhang x, zhang y. Biomark Res. 2022 Jul 29;10(1):55. doi: 10.1186/s40364-022-00400-5. Biomark Res. 2022. PMID: 35906676 Free PMC article.

8

Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).

Zhang W, Deng P, Kong T, Zhang B, Qian F, Dong Y, Chen Y, Chen L, Liu D, Zhang Y, Yang H, Han B. Zhang W, et al. Among authors: zhang b, zhang y. Lung Cancer. 2022 Nov;173:43-48. doi: 10.1016/j.lungcan.2022.09.003. Epub 2022 Sep 8. Lung Cancer. 2022. PMID: 36116169

9

International consensus on severe lung cancer-the first edition.

Zhou C, Li S, Liu J, Chu Q, Miao L, Cai L, Cai X, Chen Y, Cui F, Dong Y, Dong W, Fang W, He Y, Li W, Li M, Liang W, Lin G, Lin J, Lin X, Liu H, Liu M, Mu X, Hu Y, Hu J, Jin Y, Li Z, Qin Y, Ren S, Sun G, Shen Y, Su C, Tang K, Wu L, Wang M, Wang H, Wang K, Wang Y, Wang P, Wang H, Wang Q, Wang Z, Xie X, Xie Z, Xu X, Xu F, Yang M, Yang B, Yi X, Ye X, Ye F, Yu Z, Yue D, Zhang B, Zhang J, Zhang J, Zhang X, Zhang W, Zhao W, Zhu B, Zhu Z, Zhong W, Bai C, Chen L, Han B, Hu C, Lu S, Li W, Song Y, Wang J, Zhou C, Zhou J, Zhou Y, Saito Y, Ichiki Y, Igai H, Watanabe S, Bravaccini S, Fiorelli A, Petrella F, Nakada T, Solli P, Tsoukalas N, Kataoka Y, Goto T, Berardi R, He J, Zhong N. Zhou C, et al. Among authors: zhang b, zhang w, zhang j, zhang x. Transl Lung Cancer Res. 2021 Jun;10(6):2633-2666. doi: 10.21037/tlcr-21-467. Transl Lung Cancer Res. 2021. PMID: 34295668 Free PMC article. Review. No abstract available.

10

Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management.

Yang Z, Wang Y, Chen Y, Qian F, Zhang Y, Hu M, Zhang W, Han B. Yang Z, et al. Among authors: zhang w, zhang y. Eur J Cardiothorac Surg. 2022 Jul 11;62(2):ezac069. doi: 10.1093/ejcts/ezac069. Eur J Cardiothorac Surg. 2022. PMID: 35147672

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

81,866 results

Search Page